Monte Rosa Therapeutics (GLUE) Change in Account Payables (2020 - 2026)

Monte Rosa Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 140.25% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $1.5 million (up 244.42% YoY), while the FY2025 annual figure was -$13.7 million, down 319.26% from the prior year.
• Change in Account Payables was $4.4 million for Q1 2026 at Monte Rosa Therapeutics, up from -$10.6 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $13.3 million in Q4 2024 to a low of -$10.9 million in Q1 2025.
• Historically, Change in Account Payables has averaged $113823.5 across 5 years, with a median of $155000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables jumped 3621.29% in 2023, then tumbled 1756.86% in 2024.
• A 5-year view of Change in Account Payables shows it stood at $155000.0 in 2022, then surged by 3621.29% to $5.8 million in 2023, then surged by 130.72% to $13.3 million in 2024, then tumbled by 179.74% to -$10.6 million in 2025, then jumped by 141.25% to $4.4 million in 2026.
• The last three Change in Account Payables figures came in at $4.4 million (Q1 2026), -$10.6 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.